• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.

作者信息

Rundquist Sara, Sachs Michael C, Eriksson Carl, Olén Ola, Montgomery Scott, Halfvarson Jonas

机构信息

Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.

出版信息

Aliment Pharmacol Ther. 2021 May;53(9):1046-1047. doi: 10.1111/apt.16352.

DOI:10.1111/apt.16352
PMID:33831234
Abstract
摘要

相似文献

1
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.信函：维多珠单抗或第二种抗 TNF 药物——对炎症性肠病原发性生物制剂失效患者的疗效无差异。作者回复。
Aliment Pharmacol Ther. 2021 May;53(9):1046-1047. doi: 10.1111/apt.16352.
2
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.信函：对于炎症性肠病初次使用生物制剂失败的患者，维多珠单抗或第二种抗肿瘤坏死因子药物——疗效无差异
Aliment Pharmacol Ther. 2021 May;53(9):1044-1045. doi: 10.1111/apt.16301.
3
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.社论：抗TNF药物与维多珠单抗作为二线治疗药物的比较？平局并不意外——作者回复
Aliment Pharmacol Ther. 2021 Mar;53(5):642-643. doi: 10.1111/apt.16241.
4
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.比较抗 TNF 药物与维得利珠单抗作为炎症性肠病二线生物治疗药物的药物生存：来自全国瑞典登记处的结果。
Aliment Pharmacol Ther. 2021 Feb;53(4):471-483. doi: 10.1111/apt.16193. Epub 2020 Dec 19.
5
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
Aliment Pharmacol Ther. 2021 Mar;53(5):640-641. doi: 10.1111/apt.16212.
6
Biologic drugs for inflammatory bowel disease.用于炎症性肠病的生物药物。
Nihon Rinsho. 2017 Mar;75(3):403-407.
7
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.接受维得利珠单抗、抗 TNF 或常规治疗的炎症性肠病患者的妊娠结局：欧洲 CONCEIVE 研究结果。
Aliment Pharmacol Ther. 2020 Jan;51(1):129-138. doi: 10.1111/apt.15539. Epub 2019 Nov 6.
8
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.炎症性肠病患者对生物治疗（抗 TNF、Vedolizumab 和 Ustekinumab）的主要反应的预测因素：从基础科学到临床实践。
J Crohns Colitis. 2020 Jun 19;14(5):694-709. doi: 10.1093/ecco-jcc/jjz195.
9
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.信函：在抗TNF难治性克罗恩病中选择优特克单抗和维多珠单抗——细节决定成败。作者回复
Aliment Pharmacol Ther. 2020 Aug;52(3):563-564. doi: 10.1111/apt.15888.
10
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.炎症性肠病患者生物制剂的恰当治疗药物监测。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27.